Litigation Details for SILBERSHER v. JANSSEN BIOTECH INC. (D.N.J. 2019)
✉ Email this page to a colleague
SILBERSHER v. JANSSEN BIOTECH INC. (D.N.J. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-05-03 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 31:3729 False Claims Act | Assigned To | Kevin McNulty |
| Jury Demand | Both | Referred To | Cathy L. Waldor |
| Patents | 7,125,879; 7,157,456; 7,585,860; 7,592,339; 8,012,192; 8,022,082; 8,080,551; 8,101,629; 8,163,798; 8,518,987; 8,822,438; 8,841,310; 9,144,549 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in SILBERSHER v. JANSSEN BIOTECH INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in SILBERSHER v. JANSSEN BIOTECH INC.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for SILBERSHER v. JANSSEN BIOTECH INC. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-12-21 | 1 | Complaint | 740 Ill. Comp. Stat. 175/1-175/8 12 192. Relator realleges and incorporates by…compound patent covering Zytiga- U.S. Patent No. 5,604,213 (the 4 "'213 Patent")-expired…fraudulently obtained patent is U.S. Patent 8,822,438 (the '438 11 Patent). 12 5. …the '438 Patent 2 60. The Patent Office allowed the '438 Patent because of false… the patent's examination. The Patent Office originally rejected the '438 4 Patent application | External link to document |
| 2021-04-06 | 128 | Request for Judicial Notice | U.S. Patent No. 5,604,213 (issued Feb. 18, 1997). Exhibit B – U.S. Patent No. 8,822,438 (issued… from Certified File Wrapper of U.S. Patent No. 8,822,438, Patent Application No. 13/034,340 (filed… during the ’438 patent prosecution and are available via the PTO’s Public Patent Application Information… Documents, submitted June 4, 2013, for U.S. Patent Application No. 13/034,430 (filed Feb. 24, 2011…Specification, submitted Feb. 24, 2011, for U.S. Patent Application No. 13/034,430 (filed Feb. 24, 2011 | External link to document |
| 2021-05-20 | 146 | Brief in Opposition to Motion | as true, are: First, U.S. Patent 8,822,438 (“the ‘438 patent”), which claims the “invention” of…the Patent Act refers to the person seeking a patent repeatedly as a “party,” such that patent prosecution…statements to the Patent Office caused it to award the ’438 Patent; that the patent was the sole cause…defendants “misled the Patent Office” to obtain patents “and then used those patents to maintain their …103. Accordingly, the patent application should have been rejected by the Patent Office—and for years | External link to document |
| 2021-12-17 | 179 | Opinion | of a patent covering the pharmaceutical drug Zytiga, U.S. Patent No. 8,822,438 (“the ‘438 Patent”). Now…chemical compound patent covering Zytiga, U.S. Patent No. 5,604,213 (“the ‘213 Patent”), and in 2014, …to issued patents, published patent applications, and applications to which a patented or published…, Defendants obtained the patent at issue here, the ‘438 Patent, which claimed as its proposed invention…/17/21 Page 3 of 26 PageID: 3656 Patent as the sole patent covering Zytiga until January 2018, when | External link to document |
| 2023-03-07 | 238 | Letter | Defendants’ procurement of U.S. Patent No. 8,822,438 (the “’438 Patent”), which covered sales of the prostate…The ’438 Patent was the subject of prior patent infringement litigation (“the underlying patent litigation…of, the ’438 Patent; the granting of the ’438 Patent or the listing of the ’438 Patent in the U.S. Food…procured the ’438 Patent by knowingly submitting papers to the United States Patent Office (“USPTO”) that… for Zytiga based upon the ’438 Patent. Relator is a patent attorney with Kroub, Silbersher | External link to document |
| 2023-03-07 | 239 | Exhibit (to Document) | to apply for and prosecute U.S. Patent No. 8,822,438 (“the ’438 Patent”). (b) Defendants… 7. The term “’438 PATENT” refers to United States Patent No. 8,822,438, titled “Methods and …of, the ’438 Patent; the granting of the ’438 Patent or the listing of the ’438 Patent in the U.S. … ‘213 patent. Plaintiff further answers that the ‘438 patent is a continuation of U.S. Patent Application… the patents at issue in this litigation, or the application of patent doctrines to any patents at issue | External link to document |
| 2023-04-21 | 251 | Brief | both U.S. Patent No. 5,604,213 (“’213 patent”) and U.S. Patent No. 8,822,438 (“’438 patent”) were listed…Janssen’s Zytiga®-related patents, U.S. Patent No. 8,822,438 (“’438 patent”), which claimed a method … 1 Janssen also owned U.S. Patent No. 8,822,438 (“’438 patent”), which claimed a method of treating… the ’438 patent, seeking an order from the U.S. Patent and Trademark Office’s Patent Trial and Appeal…2016 expiration of Janssen’s U.S. Patent No. 5,604,213 (“’213 patent”), which claimed the abiraterone | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
